ArticleAnalytical and bioanalytical chemistry2025
Development and validation of an indirect competitive lateral flow immunoassay for the detection of acetaminophen (paracetamol) in bovine urine.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of an immunoassay lollipop using syringe-autoinjected visual distance readout for point-of-care testing.Analytical and bioanalytical chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Paracetamol (PCM) is a commonly used analgesic and antipyretic agent for humans worldwide. However, PCM overdoses or overuse can cause health issues, such as hepatoxicity. As PCM is also used for the treatment of farm animals, it is essential to monitor these residues in animal-derived matrices at risk-based sites in order to minimize the intake of PCM through the food chain. In the present study, we have developed a novel carbon nanoparticle (CNP)-based indirect competitive lateral flow immunoassay (icLFIA) for the rapid detection of PCM in bovine urine. The developed icLFIA can detect PCM residues within 10 min, and its performance was validated according to Commission Implementing Regulation (EU) 2021/808, i.e., determination of the detection capability (CCβ), specificity, robustness, and stability. The CCβ of the icLFIA for PCM in bovine urine is 5 mg/L and the icLFIA is proven to be selective and specific towards PCM in bovine urine, as no matrix interference and cross-reactivity were observed, except for high concentrations of orthocetamol. The icLFIA for PCM in bovine urine is robust to (small) variations in reading time, but it remains necessary to strictly use a dilution ratio of running buffer/bovine urine of 80/20. Moreover, the produced icLFIAs are stable for at least 56 days under the stored conditions. In conclusion, the developed and validated icLFIA provides a rapid and cost-effective method for on-site monitoring of PCM abuse in cattle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.